945553-94-6

Basic information

• Product Name: N-(3-Chloro-4-fluorophenyl)-6-nitro-7-(phenylsulfonyl)-4-quinazolinaMine
• Synonyms: N-(3-Chloro-4-fluorophenyl)-6-nitro-7-(phenylsulfonyl)-4-quinazolinaMine;7-(benzenesulfonyl)-N-(3-chloro-4-fluorophenyl)-6-nitroquinazolin-4-amine;(7-Benzenesulfonyl-6-nitro-quinazolin-4-yl)-(3-chloro-4-fluoro-phenyl)-amine
• CAS NO: 945553-94-6
• Molecular Formula: C₂₀H₁₂ClFN₄O₄S
• Molecular Weight: 458.8500832
• Mol File: 945553-94-6.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N-(3-Chloro-4-fluorophenyl)-6-nitro-7-(phenylsulfonyl)-4-quinazolinaMine(CAS DataBase Reference)
• NIST Chemistry Reference: N-(3-Chloro-4-fluorophenyl)-6-nitro-7-(phenylsulfonyl)-4-quinazolinaMine(945553-94-6)
• EPA Substance Registry System: N-(3-Chloro-4-fluorophenyl)-6-nitro-7-(phenylsulfonyl)-4-quinazolinaMine(945553-94-6)

Safety Data

• Hazardous Substances Data: 945553-94-6(Hazardous Substances Data)

Usage

Description

N-(3-Chloro-4-fluorophenyl)-6-nitro-7-(phenylsulfonyl)-4-quinazolinaMine is a chemical compound that belongs to the quinazoline class. It is characterized by the presence of a 3-chloro-4-fluorophenyl group, a 6-nitro group, and a 7-phenylsulfonyl group attached to the quinazolinamine core. N-(3-Chloro-4-fluorophenyl)-6-nitro-7-(phenylsulfonyl)-4-quinazolinaMine exhibits unique structural features and properties that make it a promising candidate for various applications in the pharmaceutical and chemical industries.

Uses

Used in Pharmaceutical Industry:
N-(3-Chloro-4-fluorophenyl)-6-nitro-7-(phenylsulfonyl)-4-quinazolinaMine is used as a key intermediate in the synthesis of novel 4-anilinoquinazolines. These 4-anilinoquinazolines act as inhibitors of the epidermal growth factor receptor (EGFR), which plays a crucial role in cell proliferation, differentiation, and survival. By inhibiting EGFR, these compounds can potentially be used in the treatment of various cancers, including non-small cell lung cancer, colorectal cancer, and head and neck cancer.
Used in Chemical Research:
N-(3-Chloro-4-fluorophenyl)-6-nitro-7-(phenylsulfonyl)-4-quinazolinaMine can also be utilized in chemical research for the development of new synthetic routes and methodologies. Its unique structural features can be exploited to explore novel reactions and transformations, leading to the discovery of new compounds with potential applications in various fields.

Upstream product

• 179552-73-9 7-chloro-N-(3-chloro-4-fluorophenyl)-6-nitroquinazolin-4-amine 
• 873-55-2 sodium benzenesulfonate 
• 515-42-4 sodium phenylsulfonate 
• 31374-18-2 7-chloro-3,4-dihydroquinazolin-4-one 
• 53449-14-2 7-chloro-6-nitro-4(3H)-quinazolinone 
• 162012-71-7 4,7-dichloro-6-nitro-quinazoline 
• 89-77-0 2-Amino-4-chlorobenzoic acid 
• 618-41-7 Benzenesulfinic acid 
• 367-21-5 3-chloro-4-fluorophenylamine 

Downstream Products

• 314771-88-5 4-[(3-chloro-4-fluorophenyl)amino]-6-nitro-7-[(S)-(tetrahydrofuran-3-yl)oxy]quinazoline 
• 314771-76-1 6-Amino-4-[(3-chloro-4-fluorophenyl)amino]-7-[(S)-(tetrahydrofuran-3-yl)oxy]quinazoline 

Relevant articles and documents

Novel compound having tumor diagnosis or tumor growth inhibitory activity on EGFR mutant and medical uses comprising the same

The present invention relates to a novel compound having activities of diagnosing a tumor having an epidermal growth factor receptor (EGFR) mutant and inhibiting tumor growth, a salt thereof, a contrast medium comprising the same, and a pharmaceutical composition for treating or preventing EGFR-related cancer diseases comprising the same as an active ingredient. The novel compound or the salt thereof according to the present invention does not inhibit a wild type EGFR but selectively inhibits an EGFR variant, and thus can treat and prevent EGFR-related cancer diseases, including lung cancer, colon cancer or breast cancer. Particularly, the compound or the salt thereof according to the present invention can effectively treat and prevent non-small cell lung cancer upon which Iressa or Tarceva cannot have any significant effect. In addition, the compound or the salt thereof according to the present invention responses with a target of Gefitinib-sensitive cancer cells or cancer cells showing EGFR T790M mutation rather than wild type EGFR over-expressed cancer cells, and thus can be used advisably as a contrast medium capable of clearly differentiating EGFR-related cancer cells by imaging.COPYRIGHT KIPO 2017

Design, synthesis and biological evaluation of novel 4-anilinoquinazolines with C-6 urea-linked side chains as inhibitors of the epidermal growth factor receptor

A novel series of anilinoquinazoline compounds with C-6 urea-linked side chains was designed and synthesized as reversible inhibitors of epidermal growth factor receptor (EGFR) based on the structure-activity relationships (SARs) of anilinoquinazoline inhibitors. All compounds demonstrated good inhibition of EGFR wild type (EGFR wt) (IC50 = 0.024-1.715 μM) and inhibited proliferation of A431cell line (IC50 = 0.116-22.008 μM). The binding mode of compounds 8a, 8d, 8k and 8o was consistent with the biological results. Moreover, compounds 8k and 8l almost completely blocked the phosphorylation of EGFR in A431 cell line at 0.01 μM. Interestingly, all of the compounds also demonstrated moderate inhibition of EGFR/T790M/L858R (IC 50 = 0.049-5.578 μM). In addition, compounds 8f and 8h blocked the autophosphorylation of EGFR in NCI-H1975 cells at high concentration (10 μM), and compound 8f was confirmed to be an irreversible inhibitor through the dilution method. Importantly, the compounds with C-6 urea-linked side chains which did not contain Michael acceptors demonstrated moderate to strong irreversible EGFR inhibition.